Crinetics Pharmaceuticals, Inc. (CRNX)

Import this data to Google Sheets with:

=jivedata("CRNX","financials")

Full statements spill as a table. For one cell: =jivedata("CRNX","Revenue") or =jivedata("CRNX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Crinetics Pharmaceuticals, Inc.

CRNX • CIK 0001658247

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	$7,696	$42,156
Operating Income (Loss)	$-222,608	$-338,854	$-516,769	$-549,089
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	—	—	$-465,137	$-465,137
Income Tax Expense (Benefit)	$0	$0	$180	$180
Income (Loss) from Equity Method Investments	—	—	$0	$0
Net Income (Loss) Attributable to Parent	$-214,529	$-298,408	$-465,317	$-501,606
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$-209,621	$-298,422	$-464,415	$-506,235
Cost of Revenue	—	—	$1,076	$1,430
Research and Development Expense	$168,527	$240,156	$332,058	$375,448
Selling, General and Administrative Expense	—	—	$191,331	$191,331
Costs and Expenses	—	—	$524,465	$591,245
Investment Income, Interest	$13,436	$41,435	$51,989	$48,391
Other Nonoperating Income (Expense)	—	—	$-357	$-728
Nonoperating Income (Expense)	$13,277	$40,916	$51,632	$47,663
Weighted Average Number of Shares Outstanding, Basic	58,071,000	80,783,000	94,057,000	105,443,000
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax	$4,908	$-14	$1,074	$-4,658
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	—	—	$-172	$29
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	—	—	$902	$-4,629

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$54,897	$264,545	$101,536	$55,498
Restricted Cash, Current	—	—	$0	$0
Property, Plant and Equipment, Net	$10,881	$12,068	$14,296	$13,073
Short-term Investments	$503,658	$1,089,524	$926,353	$1,150,275
Operating Lease, Right-of-Use Asset	$46,549	$43,507	$40,492	$39,107
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	$592	$11,957
Restricted Cash, Noncurrent	$1,300	$800	$800	$800
Inventory, Net	—	—	$2,022	$3,488
Prepaid Expense and Other Assets, Noncurrent	—	—	$22,327	$24,541
Prepaid Expense and Other Assets, Current	$15,598	$20,819	$17,839	$23,144
Assets	$635,353	$1,434,592	$1,126,257	$1,321,883
Assets, Current	$574,153	$1,375,388	$1,048,342	$1,244,362
Operating Lease, Liability, Noncurrent	$47,555	$44,570	$42,052	$40,606
Contract with Customer, Liability, Noncurrent	—	—	$3,810	$3,465
Other Liabilities, Noncurrent	—	$829	$3,240	$5,935
Liabilities	$96,247	$109,787	$134,174	$129,921
Accounts Payable and Accrued Liabilities, Current	$23,196	$21,469	$41,770	$42,439
Contract with Customer, Liability, Current	—	—	$1,235	$1,669
Operating Lease, Liability, Current	$4,173	$7,152	$6,489	$6,585
Liabilities, Current	$43,942	$59,684	$85,072	$79,915
Preferred Stock, Value, Issued	$0	$0	$0	$0
Common Stocks, Including Additional Paid in Capital	$1,191,831	$2,275,952	$2,407,757	$2,862,360
Accumulated Other Comprehensive Income (Loss), Net of Tax	$977	$963	$1,865	$-3,008
Retained Earnings (Accumulated Deficit)	$-653,702	$-952,110	$-1,417,427	$-1,666,127
Common Stock, Shares Held in Employee Trust	—	—	$112	$1,263
Stockholders' Equity Attributable to Parent	$539,106	$1,324,805	$992,083	$1,191,962
Debt Securities, Trading, Amortized Cost	$502,681	$1,088,561	$924,317	$1,153,283
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	200,000,000	200,000,000	200,000,000	200,000,000
Common Stock, Shares, Issued	8,333,334,000	92,926,000	95,575,000	105,808,000
Common Stock, Shares, Outstanding	68,175,000	92,926,000	95,575,000	105,808,000
Inventory, Work in Process, Net of Reserves	—	—	$2,004	$2,585
Inventory, Finished Goods, Net of Reserves	—	—	$18	$903
Interest Receivable, Current	$3,051	$8,310	$7,758	$9,566
Deferred Compensation Plan Assets	—	—	$3,249	$5,906
Other Assets, Current	$1,578	$1,207	$3,456	$4,714
Prepaid Expense and Other Assets	—	—	$40,166	$47,685
Property, Plant and Equipment, Gross	$15,949	$19,800	$22,248	$23,180
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$5,068	$7,732	$7,952	$10,107
Depreciation, Depletion and Amortization	—	—	$3,900	$3,900
Accounts Payable, Current	$6,548	$5,853	$22,611	$13,248
Other Accrued Liabilities, Current	$3,267	$891	$2,854	$4,878

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$-214,529	$-298,408	$-465,317	$-501,606
Net Cash Provided by (Used in) Operating Activities	$-166,307	$-225,970	$-377,922	$-422,515
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect	—	—	$-163,403	$1,254
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	—	—	$-106	$18
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$56,197	$265,845	$102,336	$121,608
Share-based Payment Arrangement, Noncash Expense	$40,937	$69,386	$91,024	$98,983
Payments to Acquire Debt Securities, Available-for-sale	$527,857	$1,146,772	$1,004,427	$1,139,985
Depreciation, Depletion and Amortization, Nonproduction	$1,098	$2,785	$3,890	$4,239
Operating Lease, Right-of-Use Asset, Amortization Expense	—	—	$3,014	$2,795
Proceeds from Sale and Maturity of Debt Securities, Available-for-sale	$337,132	$575,799	$1,184,097	$1,138,497
Accretion (Amortization) of Discounts and Premiums, Investments	$6,271	$14,931	$15,425	$10,578
Payments to Acquire Property, Plant, and Equipment	$4,688	$3,844	$5,762	$2,662
Net Cash Provided by (Used in) Investing Activities	$-200,413	$-574,817	$173,908	$-4,150
Equity Method Investment, Realized Gain (Loss) on Disposal	$-5,198	$-470	$0	$0
Gain (Loss) on Disposition of Property Plant Equipment	$-6	$-51	$-50	$-28
Proceeds from Issuance of Common Stock	$350,000	$970,048	$0	$380,514
Payments of Stock Issuance Costs	$22,735	$49,442	$0	$578
Net Cash Provided by (Used in) Financing Activities	$388,944	$1,010,435	$40,611	$427,919
Cash and Cash Equivalents, at Carrying Value	$54,897	$264,545	$101,536	$121,308
Restricted Cash	$1,300	$500	$800	$300
Payments of Financing Costs	$26	$0	$0	$0
Capital Expenditures Incurred but Not yet Paid	$872	$180	$389	$660
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	$46,273	$0	$0	$0
Increase (Decrease) in Accounts Receivable	—	—	$592	$11,957
Increase (Decrease) in Inventories	—	—	$2,022	$3,289
Increase (Decrease) in Prepaid Expense and Other Assets	$4,523	$5,974	$16,511	$12,673
Increase (Decrease) in Accounts Payable and Accrued Liabilities	$14,648	$17,541	$28,983	$15,051
Increase (Decrease) in Contract with Customer, Liability	—	—	$-1,835	$-763
IncreaseDecreaseInOperatingLeaseLiability	—	—	$-3,181	$-2,745

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("CRNX","financials")

Full statements spill as a table. For one cell: =jivedata("CRNX","Revenue") or =jivedata("CRNX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.